Nanoparticles and macromolecular carriers have been widely used to increase the efficacy
of chemotherapeutics, largely through passive accumulation provided by the enhanced …

The development of novel drug delivery systems based on well-defined polymer
therapeutics has led to significant improvements in the treatment of multiple disorders …

The conventional chemotherapeutic agents, used for cancer chemotherapy, have major
limitations including non-specificity, ubiquitous biodistribution, low concentration in tumor …

Cancer prevalence is increasing in the last few decades with high mortality rates. It is a
leading cause of death globally. Due to the rising prevalence of cancer and the emergence …

To achieve the promise of stimuli-responsive drug delivery systems for the treatment of
cancer, they should (1) avoid premature clearance;(2) accumulate in tumors and undergo …

Cancer is the second largest cause of death worldwide with the number of new cancer
cases predicted to grow significantly in the next decades. Biotechnology and medicine can …

In recent decades, peptides, which can possess high potency, excellent selectivity, and low
toxicity, have emerged as promising therapeutics for cancer applications. Combined with an …

Passive targeting is the foremost mechanism by which nanocarriers and drug-bearing
macromolecules deliver their payload selectively to solid tumors. An important driver of …

Targeted delivery of cancer therapeutics and imaging agents aims to enhance the
accumulation of these molecules in a solid tumor while avoiding uptake in healthy tissues …

Nano-drug delivery strategies have been highlighted in cancer treatment, and much effort
has been made in the optimization of bioavailability, biocompatibility, pharmacokinetics …